Skip to main content

Fresenius Q1/22 Results

Q1/22 Results

Fresenius with solid start to 2022 despite macroeconomic challenges

 

  • Fresenius Medical Care in line with its expectations countering significant headwinds

  • Fresenius Kabi’s solid financial performance based on strong Emerging Markets growth

  • Fresenius Helios’ strong performance driven by growing admissions in Germany and Spain

  • Fresenius Vamed with continued progress towards normal operations, very good performance in the service business

  • Ongoing headwinds from cost inflation and supply chain challenges, with uncertainty and volatility fueled by the Ukraine war

  • Guidance for 2022 confirmed

  • Fresenius appoints Sara Hennicken as Chief Financial Officer – Rachel Empey to leave company at own request

  • Dr. Carla Kriwet to succeed Rice Powell on January 1, 2023, as Chief Executive Officer of Fresenius Medical Care and member of the Fresenius Management Board 

Selected Key Figures Q1/2022

SALES

9720 m

+ 5% 1

Q1/21: €8,984 m

EBIT 2

996 m

-5% 1

Q1/21: €1,009 m

NET INCOME 2, 3

462 m

+3% 1

Q1/21: €436 m

EARNINGS PER SHARE 2, 3

0.83 m

+3% 1

Q1/21: €0.78

1 In constant currency

2 Before special items

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Sales by business segment

€ in millions Q1/22 Q1/21 ChangeOrganic sales growthCurrency translation effectsAcquisitionsDivestitures% of total sales1

Fresenius Medical Care

4,5484,2108%2%5%1%0%47%

Fresenius Kabi

1,8471,7615%1%4%0%0%19%

Fresenius Helios

2,9312,64911%8%0%3%0%30%

Fresenius Vamed

5134778%7%1%0%0%4%

Total

9,7208,9848%3%3%2%0%100%

  • 1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.

Archive